HIV Infections Clinical Trial
Official title:
Pharmacokinetics of Rifabutin Combined With Antiretroviral Therapy in the Treatment of Tuberculosis Patient With HIV Infection in South Africa: A Phase II Trial
The overall aim of the project is to evaluate rifabutin (RBT) as a replacement for
rifampicin (RMP), for the combined treatment of tuberculosis and HIV infection. RBT
represents an alternative to RMP for HIV infected patients as its half-life is longer and
the enzymatic induction effect appears to be less important on the associated antiretroviral
therapy (ART) drugs.
This phase II trial is to determine precisely the pharmacokinetics parameters of RBT in
combination with different ART regimens in Vietnamese HIV infected patients with pulmonary
tuberculosis, in order to define optimal doses that will be further tested in a larger phase
III trial comparing safety, tolerability and efficacy of RBT and RMP regimens.
Status | Completed |
Enrollment | 48 |
Est. completion date | October 2010 |
Est. primary completion date | October 2010 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years to 65 Years |
Eligibility |
Inclusion Criteria: - Pulmonary tuberculosis (proven by AFB positive sputum or culture) - Having completed and adhered to 6 wks of intensive phase TB chemotherapy - Positive HIV antibody and CD4 count >50 /mm3 and <=200 - Weight > 50 kg - No ART in the preceding 3 months - No more than 2 weeks or ART previously - No grade 3 or 4 clinical or laboratory findings - Negative pregnancy test and appropriate contraceptive measures during the duration of the trial for female of childbearing age - Having a firm home address that is readily accessible - Karnofsky score>=80% Exclusion Criteria: - History of TB within the 3 years preceding the presenting episode of TB - Previous treatment for MDR TB - Concomitant OI requiring additional anti-infectious treatment - Formal contraindication to any drug used in the trial - Diabetes mellitus requiring drug treatment - Recreational drug or alcohol abuse - History of drug hypersensitivity to TB or related medications - Interrupted TB therapy for more than 1 week - Less than 90% adherent to first 6 weeks of intensive phase chemotherapy - Mental illness that could impair ability to give informed consent or result in poor adherence to trial protocol and therapy - Neutropenia <1200 /L, anaemia <6.8 g/dL, liver function test > grade 2 - Requiring concomitant medications that may potentially interact with study drugs - Pregnant or lactating women - Karnofsky score >80% - Any condition rendering the patient unable to understand the nature, scope, and possible consequences of thes study and to provide consent |
Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
South Africa | Unit for Clinical and Biomedical TB Research (Medical Research Council) | Durban |
Lead Sponsor | Collaborator |
---|---|
French National Agency for Research on AIDS and Viral Hepatitis |
South Africa,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Area under the curve (AUC) of rifabutine measured (a)before introduction of ART;(b)after ART initiation (two different doses of RBT in combination with efavirenz, nevirapine or lopinavir/ritonavir) | 2, 6 and 10 weeks after randomisation | No | |
Secondary | Area under the curve (AUC) of efavirenz, nevirapine and lopinavir/ritonavir in combination with two doses of rifabutine | 6 and 10 weeks after randomisation | No | |
Secondary | Safety : proportion of patients with grade 3 and grade 4 adverse events | through out the trial | Yes |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05454514 -
Automated Medication Platform With Video Observation and Facial Recognition to Improve Adherence to Antiretroviral Therapy in Patients With HIV/AIDS
|
N/A | |
Completed |
NCT03760458 -
The Pharmacokinetics, Safety, and Tolerability of Abacavir/Dolutegravir/Lamivudine Dispersible and Immediate Release Tablets in HIV-1-Infected Children Less Than 12 Years of Age
|
Phase 1/Phase 2 | |
Completed |
NCT03067285 -
A Phase IV, Open-label, Randomised, Pilot Clinical Trial Designed to Evaluate the Potential Neurotoxicity of Dolutegravir/Lamivudine/Abacavir in Neurosymptomatic HIV Patients and Its Reversibility After Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide. DREAM Study
|
Phase 4 | |
Completed |
NCT03141918 -
Effect of Supplementation of Bioactive Compounds on the Energy Metabolism of People Living With HIV / AIDS
|
N/A | |
Recruiting |
NCT04579146 -
Coronary Artery Disease (CAD) in Patients HIV-infected
|
||
Completed |
NCT06212531 -
Papuan Indigenous Model of Male Circumcision
|
N/A | |
Active, not recruiting |
NCT03256422 -
Antiretroviral Treatment Taken 4 Days Per Week Versus Continuous Therapy 7/7 Days Per Week in HIV-1 Infected Patients
|
Phase 3 | |
Completed |
NCT03256435 -
Retention in PrEP Care for African American MSM in Mississippi
|
N/A | |
Completed |
NCT00517803 -
Micronutrient Supplemented Probiotic Yogurt for HIV/AIDS and Other Immunodeficiencies
|
N/A | |
Active, not recruiting |
NCT03572335 -
Systems Biology of Diffusion Impairment in Human Immunodeficiency Virus (HIV)
|
||
Completed |
NCT04165200 -
Fecal Microbiota Transplantation as a Therapeutic Strategy for Patients Infected With HIV
|
N/A | |
Recruiting |
NCT03854630 -
Hepatitis B Virus Vaccination in HIV-positive Patients and Individuals at High Risk for HIV Infection
|
Phase 4 | |
Terminated |
NCT03275571 -
HIV, Computerized Depression Therapy & Cognition
|
N/A | |
Completed |
NCT02234882 -
Study on Pharmacokinetics
|
Phase 1 | |
Completed |
NCT01618305 -
Evaluating the Response to Two Antiretroviral Medication Regimens in HIV-Infected Pregnant Women, Who Begin Antiretroviral Therapy Between 20 and 36 Weeks of Pregnancy, for the Prevention of Mother-to-Child Transmission
|
Phase 4 | |
Recruiting |
NCT05043129 -
Safety and Immune Response of COVID-19 Vaccination in Patients With HIV Infection
|
||
Not yet recruiting |
NCT05536466 -
The Influence of Having Bariatric Surgery on the Pharmacokinetics, Safety and Efficacy of the Novel Non-nucleoside Reverse Transcriptase Inhibitor Doravirine
|
N/A | |
Recruiting |
NCT04985760 -
Evaluation of Trimer 4571 Therapeutic Vaccination in Adults Living With HIV on Suppressive Antiretroviral Therapy
|
Phase 1 | |
Completed |
NCT05916989 -
Stimulant Use and Methylation in HIV
|
||
Terminated |
NCT02116660 -
Evaluation of Renal Function, Efficacy, and Safety When Switching From Tenofovir/Emtricitabine Plus a Protease Inhibitor/Ritonavir, to a Combination of Raltegravir (MK-0518) Plus Nevirapine Plus Lamivudine in HIV-1 Participants With Suppressed Viremia and Impaired Renal Function (MK-0518-284)
|
Phase 2 |